New radiation therapy targets Hard-to-Treat cancers
NCT ID NCT05204147
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug that delivers radiation directly to cancer cells that make a protein called CEA. It is for people with advanced colorectal or other CEA-positive cancers that have spread. The main goals are to find the safest dose and understand side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- Tissue analysis may guide personalized cancer therapy
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Blood test vs. scalpel: could liquid biopsy replace tissue biopsies for cancer monitoring?